FREE Shipping on all US Orders
Frontal fibrosing alopecia: the fastest-growing scarring alopecia globally — what it is, why it's increasing, and the sunscreen hypothesis the experts are still debating.
Frontal fibrosing alopecia is a progressive scarring alopecia that has increased since its first description in 1994 — now the most common scarring alopecia in postmenopausal women globally. The SOFFIA 2024 consensus (69 experts, JEADV July 2025) provides the most current international guidance. The sunscreen and cosmetic trigger hypothesis remains controversial but is taken seriously enough that a 2025 Spanish expert panel recommends avoiding organic UV filters and benzyl salicylate in FFA patients. Here is the complete honest picture.
Frontal fibrosing alopecia is distinct from every other hair loss type covered in this series in one critical way: the loss is permanent at the hairline from the point of scarring, regardless of treatment. Every other hair loss type in this series — AGA, telogen effluvium, traction alopecia, PCOS-driven loss — has a recoverable component. FFA does not. The priority is early diagnosis, stabilisation, and preventing further recession — not recovery of what is already lost.
In brief: Frontal fibrosing alopecia (FFA) is a progressive scarring alopecia that has increased steadily in prevalence since its first clinical description in 1994 — now the most commonly encountered scarring alopecia in postmenopausal women globally. It presents as progressive frontotemporal hairline recession with a characteristic pale band of skin, eyebrow and eyelash loss, and facial papules. The SOFFIA 2024 international consensus statement — 69 hair experts from 6 continents, published in JEADV on July 23, 2025 — provides the most authoritative current guidance. A Spanish expert panel (January 2025) recommends avoiding organic UV filters and benzyl salicylate in cosmetics for FFA patients. Treatment stabilises; it does not reverse established scarring.
The CCCA article covered the most common scarring alopecia in Black women. This article covers the most common scarring alopecia in postmenopausal women of all backgrounds — and the one whose prevalence is increasing most rapidly worldwide.
Frontal fibrosing alopecia is a scarring alopecia the prevalence of which is increasing worldwide since its first description in 1994. It is an inflammatory scarring hair loss that commonly affects postmenopausal women and presents as frontal hairline recession, facial papules, loss of eyebrows, and facial hyperpigmentation.
The rate of increase is striking — FFA went from a rarely documented condition to the most commonly encountered scarring alopecia in dermatology clinics across Europe and North America within three decades. As the incidence of frontal fibrosing alopecia continues to rise, there is a need for an optimal treatment algorithm for FFA. That is the opening line of the SOFFIA 2024 consensus paper — 69 experts from six continents convened to address exactly this need.
What is frontal fibrosing alopecia — and how is it diagnosed?
FFA is a form of lichen planopilaris — a lymphocytic lichenoid inflammatory condition that causes immune-mediated destruction of hair follicle stem cells in the bulge region, followed by replacement of follicle tissue with fibrous scar. Once follicles in an area are replaced by fibrous tissue, the loss in that area is permanent.
The classic clinical presentation has four features:
The most visible sign — the hairline recedes in a band across the front and temples. Unlike AGA recession in women (which thins the crown while preserving the frontal hairline), FFA recession is at the very edge of the hairline itself. A characteristic pale band of skin immediately in front of the receding hairline — the "lonely hair sign" where isolated hairs remain ahead of the main hairline — is a highly specific clinical finding for FFA. The recession is typically bilateral and symmetric, often with the frontal hairline and temples receding simultaneously rather than sequentially.
Eyebrow loss occurs in approximately 50-80% of FFA patients — often preceding or concurrent with hairline recession, and sometimes preceding it by years. The eyebrow loss follows the same inflammatory scarring mechanism as scalp loss — lymphocytic infiltration at the follicle bulge, followed by permanent fibrosis. Eyelash loss is less common but occurs. Eyebrow loss alone — particularly in a postmenopausal woman — warrants dermatological evaluation for FFA even before hairline recession becomes visible.
Approximately 30-50% of FFA patients develop small flesh-coloured papules on the face — particularly the cheeks and temples. These represent follicular inflammation in facial vellus hair follicles, the same process operating in miniaturised facial follicles as in the scalp. Body hair loss — axillary, pubic, leg hair — also occurs in a proportion of patients, reflecting the systemic nature of the inflammatory process rather than a purely localised scalp condition.
FFA diagnosis should rely on clinical and trichoscopic criteria. Trichoscopy is highly valuable, not only for initial diagnosis — recommended at the first consultation — but also for monitoring treatment response. (Spanish expert consensus, January 2025.) On trichoscopy, FFA shows a characteristic pattern: perifollicular erythema and scaling at the hairline, absent follicular openings in scarred areas, isolated hairs ahead of the main hairline, and the pale perifollicular halo that reflects the inflammatory infiltrate surrounding affected follicles. Scalp biopsy confirms the diagnosis in atypical presentations — showing lichenoid interface inflammation at the follicle bulge and fibrous tracts replacing follicle tissue.
Why is FFA increasing — and what is the sunscreen hypothesis?
The most controversial and most discussed aspect of FFA's rising prevalence is the environmental trigger hypothesis — specifically, whether sunscreen use and certain cosmetic ingredients are contributing to disease onset in genetically predisposed individuals.
Environmental triggers such as implicated cosmetic products — sunblock, personal hair care products, and moisturizers — introduce complexity to understanding FFA's pathogenesis. (JAAD, April 2026.)
The epidemiological observation: multiple studies have found that FFA patients report significantly higher rates of regular sunscreen use than age-matched controls without FFA. A 2022 Spanish cross-sectional study of 101 FFA patients and 40 controls found significantly greater sunscreen use in the FFA group. A 2022 JAAD systematic review and meta-analysis confirmed this association across pooled studies.
The honest complication: there is insufficient evidence to establish a direct causal relationship between sunscreen and FFA. The higher usage may simply reflect a new behaviour adopted because of the alopecia, or may reflect higher socioeconomic status. Moreover, the increasing number of FFA cases in Black-skinned patients, among whom rates of sunscreen use are generally low, is also less consistent with the sunscreen causality hypothesis.
Despite the unproven causality, the association has been taken seriously enough to influence clinical practice. The Spanish expert panel recommended avoiding products containing organic soluble UV filters (in sunscreens) and benzyl salicylate (in cosmetics) in FFA patients, based on available evidence and the precautionary principle. (January 2025 consensus.)
The proposed mechanism — not proven but plausible: organic UV filters (the chemical filters as opposed to mineral/physical UV blockers like zinc oxide and titanium dioxide) may act as endocrine disruptors in the skin environment, potentially triggering the inflammatory lichenoid response in genetically susceptible individuals. Endocrine disruptors present in some cosmetic and sunscreen products may contribute to disease onset in these patients.
How is FFA different from other scarring alopecias?
What does current treatment for FFA look like?
No prescription medications are covered in this series. This section describes the treatment landscape honestly for awareness — not as a prescription recommendation.
Treatment strategies including combination therapies such as hydroxychloroquine, dutasteride, topical and intralesional steroids, and topical tacrolimus offer hope in stabilizing the condition. (JAAD April 2026.) The key word is stabilising — FFA treatment aims to halt progression, not to reverse established scarring loss. Hair that has been lost to scarring at the hairline cannot regrow. What treatment can do is stop the active inflammatory process and prevent further recession.
The SOFFIA 2024 consensus reached agreement on trichoscopy as the primary monitoring tool, with physical signs of active inflammation (perifollicular erythema, scaling) indicating active disease requiring treatment and the absence of these signs indicating stable disease. The consensus highlighted significant disagreement among experts on several treatment questions — reflecting the genuine uncertainty in this field.
The non-prescription layer that this series can address: for FFA patients, avoiding organic UV filters in sunscreen (switching to mineral SPF with zinc oxide or titanium dioxide) and avoiding benzyl salicylate in cosmetics is a reasonable precautionary step supported by the Spanish expert panel, while the causal relationship remains under investigation.
Frequently Asked Questions
What is frontal fibrosing alopecia?
A progressive scarring alopecia that causes permanent hairline recession at the frontotemporal hairline, eyebrow and eyelash loss, and facial papules — primarily in postmenopausal women, though increasing in premenopausal women and men. It is a form of lichen planopilaris — a lymphocytic inflammatory condition that scars hair follicle stem cells. Loss in scarred areas is permanent; treatment aims to stabilise and halt progression.
How do I know if I have FFA or regular hairline recession?
The distinguishing features of FFA: recession at the very edge of the hairline (not diffuse thinning behind it), pale band of skin immediately ahead of the receding line, eyebrow or eyelash loss accompanying the hairline recession, and facial papules. Trichoscopy by a dermatologist is the most reliable diagnostic tool — showing perifollicular inflammation and absent follicular openings in scarred areas. Any hairline recession accompanied by eyebrow loss warrants dermatological evaluation for FFA regardless of age.
Does sunscreen cause frontal fibrosing alopecia?
The causal relationship has not been proven. Multiple studies confirm FFA patients report higher rates of sunscreen use than controls — but whether sunscreen contributes to triggering FFA in susceptible individuals, or whether the association reflects other factors, remains unresolved. The Spanish expert panel (January 2025) recommends FFA patients avoid organic UV filters (chemical sunscreen filters) and benzyl salicylate in cosmetics as a precautionary measure. Mineral sunscreens (zinc oxide, titanium dioxide) are not implicated.
Can frontal fibrosing alopecia be reversed?
No — established scarring at the hairline is permanent. Hair follicles replaced by fibrous tissue cannot regenerate. Treatment can halt the active inflammatory process and prevent further recession. This is why early diagnosis is the highest-priority action — the earlier FFA is identified and stabilised, the less permanent loss accumulates before treatment begins.
Who should I see for frontal fibrosing alopecia?
A dermatologist with specific trichology or hair loss expertise — FFA requires trichoscopy and potentially scalp biopsy for diagnosis, and treatment management involves medications that require specialist oversight. The SOFFIA 2024 consensus involved 69 international hair experts specifically because FFA management requires specialist knowledge. A general dermatologist may refer to a trichologist or hair loss specialist for complex cases.
The honest summary.
Frontal fibrosing alopecia is the scarring alopecia type that most demands early recognition — because the loss is permanent from the point of scarring, and because the rate of progression varies enough that some patients stabilise while others experience rapid recession. The SOFFIA 2024 consensus represents the most current international agreement on what is known and what is still debated.
The practical actions available to anyone reading this who is concerned about FFA: if you have hairline recession accompanied by eyebrow thinning or loss, seek trichoscopy evaluation now rather than waiting. If you have been diagnosed with FFA, switching from chemical to mineral sunscreen (zinc oxide/titanium dioxide) is the precautionary step the Spanish expert panel recommends — low risk, no cost to skin protection, and consistent with the current understanding of possible environmental triggers.
Of all the hair loss types this series has covered, FFA is the one where the equation most clearly favours urgency: early diagnosis, early stabilisation, prevention of further loss. The window for intervention is not measured in years — it is measured in how much hairline is left to protect.
The case for early diagnosis has never been more clear.
Clean botanical scalp care — no organic UV filters, no benzyl salicylate.
The Laritelle formulas use certified organic botanical ingredients with no synthetic UV filters or benzyl salicylate — consistent with the precautionary approach the Spanish expert panel recommends for FFA patients.
→ Explore Hair Treatments → Find Your FormulaScience, ritual, and botanical intelligence — delivered daily.
Each morning, one article. New research, ancient wisdom, and the honest science of hair and scalp health. Written for women who want to understand what is happening — not just what to buy.
By subscribing you agree to receive email from Laritelle Organic. Unsubscribe at any time.